SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Handgrip test for lung cancer survival chances
Fri April 20th - Testing handgrip strength can help predict the survival chances of patients with non-small cell lung cancer, a conference will hear this weekend. More
NHS genomics project “at risk” - MPs
Fri April 20th - Ambitious plans to make the NHS a world leader in genomics are at risk, MPs warn today. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
BOOKS ON WOMEN'S HEALTH
guide to breast disorders guide to womb disorders guide to menopause Complete Women's Health: from The Royal College of Obstetricians and Gynaecologists For more books and family gift ideas click here
OTHER NEWS OF INTEREST
WOMEN'S HEALTH NEWS FEED
RSS graphic XML Graphic
ENGLEMED HEALTH NEWS

New drug class unveiled at Imperial

Wednesday April 11th, 2018

British researchers have announced the development of a new class of drug developed to treat drug-resistant tumours.

The drug ICEC0942 targets the enzyme CDK7, which is involved in the transcription process.

Yesterday scientists at Imperial College, London, reported the properties of the drug in the journal Molecular Cancer Therapeutics.

It is already undergoing testing in a phase I clinical trial and the first patient received it last November, taking it in oral form.

It was previously tested in laboratory models on treatment-resistant breast cancers, the researchers say – and this indicated minimal side-effects.

The researchers are hoping it may also work with other transcription-dependent cancers, such as acute myeloid leukaemia and small-cell lung cancer.

Oncologist Professor Charles Coombes said: "Drugs such as these could help to shift the balance back in favour of the patients, potentially providing a new option to patients for who existing treatments no longer work."

Dr Iain Foulkes, from Cancer Research UK, said: “We hope that this promising new class of drug will offer more options to patients who have few left available to them, and help more people survive their cancer."

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Molecular Cancer Therapeutics 15 March 2018

http://mct.aacrjournals.org/content/early/2018/03/15/1535-7163.MCT-16-0847

Tags: Cancer | Pharmaceuticals | UK News | Women's Health & Gynaecology

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES